A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.
Br J Cancer
; 115(8): 940-948, 2016 10 11.
Article
en En
| MEDLINE
| ID: mdl-27575850
ABSTRACT
BACKGROUND:
Only a small proportion of patients respond to anti-VEGF therapy, pressing the need for a reliable biomarker that can identify patients who will benefit. We studied the biological activity of anti-VEGF antibodies in patients' blood during anti-VEGF therapy by using the Ba/F3-VEGFR2 cell line, which is dependent on VEGF for its growth.METHODS:
Serum samples from 22 patients with cancer before and during treatment with bevacizumab were tested for their effect on proliferation of Ba/F3-VEGFR2 cells. Vascular endothelial growth factor as well as bevacizumab concentrations in serum samples from these patients were determined by enzyme linked immunosorbent assay (ELISA).RESULTS:
The hVEGF-driven cell proliferation was effectively blocked by bevacizumab (IC50 3.7 µg ml-1; 95% CI 1.7-8.3 µg ml-1). Cell proliferation was significantly reduced when patients' serum during treatment with bevacizumab was added (22-103% inhibition compared with pre-treatment). Although bevacizumab levels were not related, on-treatment serum VEGF levels were correlated with Ba/F3-VEGFR2 cell proliferation.CONCLUSIONS:
We found that the neutralising effect of anti-VEGF antibody therapy on the biological activity of circulating VEGF can be accurately determined with a Ba/F3-VEGFR2 bioassay. The value of this bioassay to predict clinical benefit of anti-VEGF antibody therapy needs further clinical evaluation in a larger randomised cohort.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Bioensayo
/
Ensayo de Inmunoadsorción Enzimática
/
Linfocitos B
/
Inhibidores de la Angiogénesis
/
Receptor 2 de Factores de Crecimiento Endotelial Vascular
/
Factor A de Crecimiento Endotelial Vascular
/
Bevacizumab
/
Neoplasias
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Br J Cancer
Año:
2016
Tipo del documento:
Article
País de afiliación:
Países Bajos